

# Performance of the PA<sub>X</sub>*press*<sup>TM</sup> vs the ProSeal<sup>TM</sup> laryngeal mask airway during general anesthesia

[*Efficacité du PA<sub>X</sub>*press*<sup>TM</sup> et du masque laryngé ProSeal<sup>TM</sup> durant l'anesthésie générale*]

Alexandre Lallo MD FRCPC, Pierre Drolet MD FRCPC, Mélanie Lacroix MD FRCPC

**Purpose:** The PA<sub>X</sub>*press*<sup>TM</sup> (PA<sub>X</sub><sup>TM</sup>) is a relatively new pharyngeal airway device that is easily inserted and effective in routine airway management. A prospective, randomized study was undertaken to compare the PA<sub>X</sub><sup>TM</sup> with the ProSeal<sup>TM</sup> laryngeal mask airway (PLMA<sup>TM</sup>) during anesthesia with positive pressure ventilation.

**Methods:** One hundred adult patients scheduled for elective surgery under general anesthesia were randomized to airway management with either the PA<sub>X</sub><sup>TM</sup> ( $n = 50$ ) or the PLMA<sup>TM</sup> ( $n = 50$ ). All patients swallowed a methylene blue capsule before anesthesia. After insertion, leak and inspiratory pressures were measured. Fibrescopy was used to view the glottis. Devices were inspected for blood or methylene blue staining upon removal at the end of surgery. An interview was conducted postoperatively to evaluate the occurrence of sore throat, dysphagia and dysphonia.

**Results:** Insertion time was longer for the PA<sub>X</sub><sup>TM</sup> than for the PLMA<sup>TM</sup> ( $52 \pm 44$ s vs  $34 \pm 23$  sec;  $P = 0.003$ ). Leak pressure was lower while peak inspiratory pressures, and EtCO<sub>2</sub> values were higher ( $P = 0.016$ ; 0.027 and 0.04 respectively) with the PA<sub>X</sub><sup>TM</sup>. Both devices provided comparable fibroscopic viewing of the glottis. There were no differences with respect to the incidence or pattern of blue stains upon removal. Blood was seen more often on the PA<sub>X</sub><sup>TM</sup> (58% vs 19%) and dysphagia was also more frequent and severe with the PA<sub>X</sub><sup>TM</sup>.

**Conclusion:** In comparison with the PLMA<sup>TM</sup>, PA<sub>X</sub><sup>TM</sup> insertion time is longer and the ventilatory characteristics of this new device may be marginally inferior. The PA<sub>X</sub><sup>TM</sup> is also more traumatic and is associated with more postoperative discomfort compared to the PLMA<sup>TM</sup>.

CAN J ANESTH 2007 / 54: 1 / pp 28–33

**Objectif:** Le PA<sub>X</sub>*press*<sup>TM</sup> (PA<sub>X</sub><sup>TM</sup>) est un dispositif pharyngé de contrôle des voies aériennes relativement nouveau ; il s'insère facilement et est efficace dans la pratique de tous les jours. Une étude prospective et randomisée a été entreprise afin de comparer le PA<sub>X</sub><sup>TM</sup> au masque laryngé ProSeal<sup>TM</sup> (PLMA<sup>TM</sup>) pendant une anesthésie avec ventilation à pression positive.

**Méthodes :** Cent patients adultes devant subir une chirurgie élective sous anesthésie générale ont été randomisés à l'une de deux stratégies de gestion des voies aériennes : le PA<sub>X</sub><sup>TM</sup> ( $n = 50$ ) ou le PLMA<sup>TM</sup> ( $n = 50$ ). Tous les patients ont avalé une capsule de bleu de méthylène avant l'anesthésie. Après insertion, les pressions inspiratoires et de fuite ont été mesurées. Un fibroscope a été utilisé pour visualiser la glotte. Les dispositifs ont été inspectés pour détecter des taches de sang ou de bleu de méthylène lorsqu'ils sont retirés à la fin de la chirurgie. Une entrevue postopératoire a été menée afin d'évaluer l'incidence de maux de gorge, de dysphagie et de dysphonie.

**Résultats :** Le temps d'insertion a été plus long pour le Pax<sup>TM</sup> que pour le PLMA<sup>TM</sup> ( $52 \pm 44$ s vs  $34 \pm 23$  sec;  $P = 0.003$ ). Les pressions de fuite étaient plus faibles et les pressions inspiratoires maximum et les valeurs de CO<sub>2</sub> expiré (Et CO<sub>2</sub>) étaient plus élevées ( $P = 0.016$ ; 0.027 et 0.04 respectivement) avec le PA<sub>X</sub><sup>TM</sup>. Les deux appareils ont permis une visualisation comparable de la glotte par fibroscopie. Il n'y a pas eu de différence au niveau de l'incidence ou de la présence de taches bleues lors du retrait des dispositifs. Du sang était cependant plus fréquemment observé sur le PA<sub>X</sub><sup>TM</sup> (58% vs 19%), de même qu'une dysphagie plus courante et sévère avec le PA<sub>X</sub><sup>TM</sup>.

**Conclusion :** Comparé au PLMA<sup>TM</sup>, le temps d'insertion du PA<sub>X</sub><sup>TM</sup> est plus long et les caractéristiques de ventilation de ce nouveau dispositif sont légèrement inférieures. Le PA<sub>X</sub><sup>TM</sup> est également plus traumatisant et est associé à davantage d'inconfort postopératoire que le PLMA<sup>TM</sup>.

From the Department of Anesthesiology, University of Montreal, Montreal, Quebec, Canada.

*Address correspondence to:* Dr. Alexandre Lallo, Department of Anesthesiology, CHUM, Hôpital Notre-Dame, 1560, Sherbrooke East, Montreal, Quebec H2L 4M1, Canada. Phone: 514-890-8000, ext. 26876; Fax: 514-412-7653; E-mail: a.lallo@umontreal.ca

*Funding:* Airway devices were provided free of charge by Vitaid limited, Toronto ON, Canada (Proseal) and Trudell Medical Marketing Limited, London ON, Canada (PA<sub>X</sub>*press*).

*Accepted for publication June 23, 2006.*

*Revision accepted October 10, 2006.*

*Competing interests:* None declared.

THE PA<sub>X</sub><sup>press™</sup> oropharyngeal airway (PA<sub>X</sub><sup>TM</sup>) (Figure 1) is a relatively new supraglottic airway device proposed as an alternative to other ventilatory tools such as the LMA<sup>TM</sup> and the COPA<sup>TM</sup>. The anatomically curved tube of the PA<sub>X</sub><sup>TM</sup> comprises a circular, low pressure, oropharyngeal cuff intended to seal the airway while pushing the tongue slightly forward for improved ventilation. A flexible gilled tip is tapered to guide insertion and rest within the cricopharyngeal recess, above the esophageal sphincter. Ventilation occurs through an open hooded window on the anterior part of the tube, which aligns with the glottic opening. The PA<sub>X</sub><sup>TM</sup> can also be used for tracheal tube placement. It has been shown to be an easily inserted, effective airway device.<sup>1–3</sup>

The ProSeal<sup>TM</sup> (PLMA<sup>TM</sup>) is a modified version of the classic LMA<sup>TM</sup> with a modified cuff to improve the seal and a drainage tube to isolate the glottis from the esophagus.<sup>4</sup> Although its insertion has been shown to be longer and first time insertion success rates slightly lower, the PLMA<sup>TM</sup> provided higher airway sealing pressures when compared to the classic LMA<sup>TM</sup>,<sup>5,6</sup> without causing more sore throats or intraoperative complications.

The purpose of this prospective, randomized study was to compare the efficacy of the PA<sub>X</sub><sup>TM</sup> and the PLMA<sup>TM</sup> with respect to oropharyngeal leak pressure and adequacy of ventilation during volume-controlled ventilation. As secondary outcomes we evaluated adequacy of positioning and the incidence of regurgitation based upon methylene blue stains on airway devices. The null hypothesis was that there would be no difference between devices with respect to oropharyngeal leak pressure.

## Methods

After approval from our Institutional Review Board and obtaining written informed consent from each participant, 100 adult patients (ASA physical status I–III) undergoing general anesthesia for elective surgery were randomly assigned to have either a PA<sub>X</sub><sup>TM</sup> (Vital Signs Inc., NJ, USA) ( $n = 50$ ) or a PLMA<sup>TM</sup> (The Laryngeal Mask Company, Henley-on-Thames, UK) ( $n = 50$ ) for airway management. Randomization was done in blocks of ten patients and allocation concealment was achieved by drawing numbers from a sealed envelope. Excluded were patients with symptomatic gastroesophageal reflux/disease, a body mass index  $> 35 \text{ kg} \cdot \text{m}^{-2}$  and need for placement of a gastric tube. One operator (A.L.), experienced with both the PLMA<sup>TM</sup> and the PA<sub>X</sub><sup>TM</sup>, inserted all airway devices.

Each participant swallowed a gelatin capsule containing 50 mg of methylene blue with 20–30 mL of




FIGURE 1 The PA<sub>X</sub><sup>press™</sup> comprises A- flexible gilled tip designed to rest above the esophageal sphincter, B- ventilatory conduit ending with an open hooded window, C- circular low pressure oropharyngeal cuff intended to seal the airway.

water, ten to 15 min prior to the induction of anesthesia. Anesthetic management was standardized and routine monitoring was applied to all patients. After preoxygenation with 100% O<sub>2</sub> for three minutes, anesthesia was induced with fentanyl 1–3 µg·kg<sup>-1</sup> iv and propofol 1.5–3.5 mg·kg<sup>-1</sup> iv. Muscle relaxation was achieved in all participants using rocuronium 0.6 mg·kg<sup>-1</sup> iv. Ventilation was provided via face mask with 100% O<sub>2</sub> until insertion of the selected airway device, two minutes after rocuronium injection. Either a PA<sub>X</sub><sup>TM</sup> of universal adult size or a PLMA<sup>TM</sup> (size 4 for women and 5 for men)<sup>7</sup> was used, according to group allocation. The PA<sub>X</sub><sup>TM</sup> was inserted according to the manufacturer's instruction manual. The cuff was first deflated and smoothed proximally. Lubricating jelly was then applied to the cuff and on both sides of the gilled tip. With the patient in a slight sniffing position, the PA<sub>X</sub><sup>TM</sup> was inserted in the mouth and the tip pushed backward and downward along the patient's midline, while maintaining contact with the hard palate, soft palate, and posterior pharyngeal wall until resistance was felt in the hypopharynx. The cuff was then inflated with 30 mL of air (50% of the maximal recommended volume). If an audible leak was present when attempting manual ventilation, the cuff was further inflated in 10 mL increments (maximum 60 mL) to obtain an effective seal. The PLMA<sup>TM</sup> was also inserted according to the manufacturer's instructions, without the introducer tool. It was first inflated at 50% of the maximal recommended cuff volume (PLMA<sup>TM</sup> 4/5: 15/20 mL) and volume was added in 5-mL increments until no audible leak was heard and

an effective airway was obtained (maximum volumes for PLMA™ 4/5: 30/40 mL). Three attempts were allowed for placement of each device and, if necessary, mask ventilation with sevoflurane 1–3% in oxygen was provided between attempts. A jaw-thrusting maneuver was used at the second attempt to aid placement and a laryngoscope was used for the third attempt. Three unsuccessful attempts were considered to be an insertion failure, after which an alternative airway device was used. The total time of placement, from insertion of the device in the mouth to the establishment of effective ventilation (no audible leak, symmetrical movement of the thorax and a square wave capnograph trace) was recorded. The number of attempts was also documented.

After confirming establishment of an effective airway, devices were connected to a circle breathing system and controlled ventilation (Ohio V5® ventilator, Ohio medical products, Airco Inc., WI, USA) was adjusted to deliver 10 mL·kg<sup>-1</sup> of body weight at a rate of 10 breaths·min<sup>-1</sup> with an I:E ratio of 1:2. Spirometry and EtCO<sub>2</sub> concentration were monitored (Capnomac Ultima, Datex-Ohmeda, Helsinki, Finland). After 30 sec of stable ventilation with sevoflurane in oxygen, the oropharyngeal leak pressure was measured at 50% and 100% of the maximal recommended inflation cuff volume for each device. This measurement was achieved by closing the expiratory valve of the circle system at a fixed gas flow rate of 3 L·min<sup>-1</sup> and noting the airway pressure (maximum 40 cm H<sub>2</sub>O) at which equilibrium was attained.<sup>8</sup> Once the leak pressures were noted, a fibrescope was introduced just proximal to the end of the ventilatory conduit of each device, and the laryngeal view was graded using an established scoring system (4 = only vocal cords visible; 3 = vocal cords and posterior epiglottis visible; 2 = vocal cords and anterior epiglottis visible; 1 = vocal cords not seen).<sup>9</sup> Two minutes after fibrescopic visualization, the expired tidal volume, peak airway pressure, oxygen saturation and end-tidal carbon dioxide were recorded. The inspired oxygen fraction (F<sub>i</sub>O<sub>2</sub>) was then adjusted to keep SpO<sub>2</sub> > 95% (minimal F<sub>i</sub>O<sub>2</sub> = 0.3). Anesthesia was maintained with sevoflurane, fentanyl and rocuronium. Any intervention on the airway was also noted and graded as either minor (adjusting head/neck position, changing depth of insertion or adding air to the cuff) or major (requiring jaw thrust, reinsertion/change of device).

After completion of surgery and reversal of residual neuromuscular block, sevoflurane was discontinued and the airway device was removed from the patient's mouth upon awakening. Immediately after removal, the device was inspected for traces of blood or methy-




FIGURE 2 Graded methylene blue staining scale: 0- no visible stain, 1- stains visible only on parts of the devices not directly in contact with the respiratory tract, 2- stains partly on parts of the devices in direct contact with the respiratory tract, 3- stains entirely on parts of the devices in direct contact with the respiratory tract.

lene blue. Methylene blue staining was graded according to a scale previously described for the LMA<sup>10</sup> and adapted to the PA<sub>X</sub><sup>TM</sup> (Figure 2). Additionally, a structured interview was conducted with the patients 18 to 24 hr postoperatively. Patients were asked specifically about sore throat (pain independent of phonation or deglutition), dysphagia (difficulty or pain during swallowing), and dysphonia (pain on phonation/ altered voice). Each item was graded as absent, light, moderate or severe.

Sample size was determined based on a reported SD value of 6 cm H<sub>2</sub>O for leak pressure.<sup>10</sup> This protocol was designed to detect a 4-cm H<sub>2</sub>O difference in oropharyngeal leak pressure, accepting alpha and beta errors of 0.05 and 0.2 respectively. According to these parameters, a total of 36 patients per group were needed. Considering possible exclusions or failed attempts at positioning the devices, we decided to include 50 patients in each group. Student's *t* test was used to compare continuous variables exhibiting normal distribution. Chi-square, Fisher's exact test and Mann-Whitney U test were used for non-continuous variables and continuous variables with non-normal distribution. *P* values < 0.05 were considered significant.

TABLE I Demographic and surgical data

	<i>PAx</i> ™ (n = 48)	<i>PLMA</i> ™ (n = 48)
Age (yr)*	48 ± 15	48 ± 14
Sex (male/female)	10/40	11/39
Weight (kg)*	69 ± 15	70 ± 15
Height (m)*	1.65 ± 0.10	1.64 ± 0.10
Body mass index*	25.2 ± 4.5	25.8 ± 3.6
Position (supine/lithotomy)	32/18	30/20
Length of surgery (min)*	75 ± 36	72 ± 43

*PAx*™ = *PAxpress*™; *PLMA*™ = ProSeal™ laryngeal mask airway.

\*Mean ± SD.

## Results

A total of 100 patients were randomized, and 96 completed the protocol. Patient characteristics were similar in the two groups (Table I). There were no differences between groups with respect to the duration of surgery or the surgical positioning (supine/lithotomy) of the participants.

There were two failures of insertion in each group (4%) (Table II). Mean insertion times were longer (52 ± 44 sec) for the *PAx*™ compared to the *PLMA*™ (34 ± 23 sec) ( $P = 0.0003$ ). The groups were similar with respect to first-time insertion success rates (76% for *PAx*™ vs 84% for the *PLMA*™). However, the oropharyngeal leak pressure at 50% of maximum cuff inflation was higher ( $P = 0.016$ ) for the *PLMA*™ (22 ± 7 cm H<sub>2</sub>O) compared to the *PAx*™ (18 ± 8 cm H<sub>2</sub>O), but there was no difference between groups when both cuffs were fully inflated. There was also no difference between groups with respect to the visualization scores of the cords. Peak airway pressure and

EtCO<sub>2</sub>, two minutes after fibrescopic examination, were greater in the *PAx*™ group (19 ± 6 cm H<sub>2</sub>O and 33 ± 4 mmHg) than in the *PLMA*™ group (16 ± 4 cm H<sub>2</sub>O and 31 ± 3 mmHg). Blood was seen more often, upon removal, on the *PAx*™ than on the *PLMA*™ (58% vs 19% of patients,  $P = 0.0001$ ). There was no difference with respect to the incidence or pattern of methylene blue staining on either device. The postoperative interview revealed that dysphagia was significantly more frequent in the *PAx*™ group than in the *PLMA*™ group (79% vs 50% of patients,  $P = 0.002$ ). In all other respects, secondary outcome measures in the two groups were similar.

## Discussion

Supraglottic devices are now an important part of airway management during anaesthesia. Desirable characteristics for such devices include ease of insertion and minimal trauma. They should also act as effective conduits for controlled ventilation, while providing some degree of airway protection against regurgitated material arising from the gastrointestinal tract. Because the *PLMA*™ exhibits most of these characteristics to various degrees, the device is considered by many anaesthesiologists to be the most appropriate supraglottic tool available for positive pressure ventilation. The *PAx*™ is a new device that is designed to act as an effective ventilatory conduit while occluding the oesophagus, thus providing some protection against gastroesophageal reflux. In spite of certain similarities with the *PLMA*™, there are some important differences which distinguish these devices. The *PAx*™ is built to act as an effective conduit for passage of an endotracheal tube, but it does not provide a means for venting the oesophagus or insert a gastric tube. This

TABLE II Results: *PAx*™ vs *PLMA*™

	<i>PAx</i> ™ (n = 48)	<i>PLMA</i> ™ (n = 48)	<i>P value</i>
Insertion time (sec)*	52 ± 44	34 ± 23	0.0003
Attempts (1/2/3/Failure)	38/8/2/2	42/5/1/2	0.747
Oropharyngeal leak pressure (cm H <sub>2</sub> O)*			
-50% recommended cuff volume	18 ± 8	22 ± 7	0.016
-100% recommended cuff volume	27 ± 7	30 ± 7	0.0946
Fibrescopic glottic view (grade 1/2/3/4)	8/16/9/15	4/10/19/15	0.0983
Peak airway pressure (cm H <sub>2</sub> O)*	19 ± 6	16 ± 4	0.0268
EtCO <sub>2</sub> (mmHg)*	33 ± 4	31 ± 3	0.04
Blood on device (yes/no)	28/20	9/39	0.0001
Blue stain (grade 0/1/2/3)†	41/2/1/4	41/3/1/3	0.951
Interventions on the airway (none/1/2/3/4)	Minor†	37/9/0/1/1	0.255
	Major†	43/5/0/0/0	0.056
Postoperative interview (none/light/moderate/severe)	Sore throat	23/13/6/2	0.210
	Dysphagia	10/13/15/6	0.002
	Dysphonia	27/11/6/0	0.99

*PAx*™ = *PAxpress*™; *PLMA*™ = ProSeal™ laryngeal mask airway.\*Mean ± SD; †See text for detailed description.

study was conceived to compare characteristics that are common to both devices, and their effectiveness. That is why neither the possibility of intubating the trachea or inserting a gastric tube through the supraglottic airways was studied. These additional characteristics should be considered when selecting the most appropriate airway for a given patient.

This study suggests that, although the PA<sub>X</sub><sup>TM</sup> is a viable alternative for controlled ventilation during general anesthesia, it takes longer to insert, it provides slightly less effective ventilation, and it may be more traumatic in comparison to the PLMA<sup>TM</sup>. Although the placement time of the PA<sub>X</sub><sup>TM</sup> was slightly longer in comparison to the PLMA<sup>TM</sup>, the clinical importance of this modest difference needs to be considered on a case-by-case basis. It is important to note that in the majority of patients successful insertion was achieved on the first attempt. First attempt insertion rates observed for the PLMA<sup>TM</sup> (84%) and the PA<sub>X</sub><sup>TM</sup> (76%) in our study are similar to observations from other studies.<sup>1,2,11-13</sup> The failure rate was low (4%) for both devices.

There was a slight difference in the airway sealing pressure between the two devices at 50% of the recommended maximal cuff volume, but no difference was observed when cuffs were inflated to their maximal recommended volumes. Given the different designs of the two devices, the clinical significance of variances in sealing pressures is uncertain, although in some circumstances the PLMA<sup>TM</sup> is likely to provide slightly higher sealing pressures than the PA<sub>X</sub><sup>TM</sup>. The PLMA<sup>TM</sup> oropharyngeal leak pressure observed in this study was comparable to that found in other reports.<sup>6,11,14</sup> Also, the peak airway pressure and EtCO<sub>2</sub> values at standardized tidal volume were higher for the PA<sub>X</sub><sup>TM</sup> compared to the PLMA<sup>TM</sup>. Although statistically significant, the clinical importance of these differences is likely to be modest. Still, cumulative findings suggest, again, that the PLMA<sup>TM</sup> may be a slightly more effective device from a ventilatory standpoint. The small differences in the ventilatory characteristics between both devices could not be explained by the fibrescopic observations, since both devices allowed comparable views of the cords and their surrounding structures.

The incidence and patterns of observed methylene blue stains upon removal of the studied devices were similar in the two groups. According to the scale used in this study, grade 2 and 3 patterns represented situations in which the observed staining was in direct contact with the glottis and the lower respiratory tract. Five patients in the PA<sub>X</sub><sup>TM</sup> group and four patients in the PLMA<sup>TM</sup> group exhibited such stain patterns. Although the clinical significance of these observa-

tions is uncertain, these results suggest that both devices allowed for some material to migrate from the esophageal to the respiratory tract during the conduct of anesthesia. None of the nine patients with grade 2 or 3 stain patterns exhibited clinical signs of bronchial aspiration or pulmonary complications.

Blood was found three times more frequently upon removal of the PA<sub>X</sub><sup>TM</sup> compared to the PLMA<sup>TM</sup> (19% vs 58%). These results are in accordance with previous reports for both devices,<sup>1,6,12</sup> and with other data showing higher hemodynamic changes upon insertion of the PA<sub>X</sub><sup>TM</sup> when compared to the Classic LMA<sup>TM</sup>.<sup>3</sup> Such observations suggest that trauma is more likely to occur if the PA<sub>X</sub><sup>TM</sup> is used instead of the PLMA<sup>TM</sup>. The tip of the PA<sub>X</sub><sup>TM</sup> used in this study was gilled on one side and smooth on the other (dorsal), as opposed to a previous model, which had gills on both sides. In spite of this modification, the incidence of trauma was still quite high in our study and in a majority of cases the blood was located, at least in part, on the gilled side of the tip. The more severe and more frequently observed dysphagia in the PA<sub>X</sub><sup>TM</sup> group suggests that this device is more traumatic compared to the PLMA<sup>TM</sup>.

This study protocol did not allow blinding of the operator inserting the airway devices. This is a source of potential systematic bias. Also, since the sample size was calculated using expected differences in oropharyngeal leak pressure, the study may be underpowered to demonstrate significant differences in some of the secondary endpoints, such as visualization of the glottis, incidence of regurgitation and dysphonia.

In conclusion, the PAx<sup>TM</sup> is an effective supraglottic airway device for positive pressure ventilation during routine surgery. However, in comparison to the PLMA<sup>TM</sup>, it requires slightly more time to insert and it is associated with higher peak airway pressures and end-tidal CO<sub>2</sub> values. The PAx<sup>TM</sup> is also more traumatic and is associated with more postoperative discomfort compared to the PLMA<sup>TM</sup>.

## References

- Dimitriou V, Voyagis GS, Iatrou C, Brimacombe J. The PAxpress is an effective ventilatory device but has an 18% failure rate for flexible lightwand-guided tracheal intubation in anesthetized paralyzed patients. *Can J Anesth* 2003; 50: 495-500.
- Dimitriou V, Voyagis GS, Iatrou C, Brimacombe J. A comparison of the PAxpress and face mask plus Guedel airway by inexperienced personnel after mannequin-only training. *Anesth Analg* 2003; 96: 1214-7.
- Casati A, Vinciguerra F, Spreafico E, et al. Cardiovascular changes after extraglottic airway inser-

- tion: a prospective, randomized comparison between the laryngeal mask or the new PAxpress. *J Clin Anesth* 2004; 16: 342–6.
- 4 *Brain AI, Verghese C, Strube PJ*. The LMA ‘ProSeal’--a laryngeal mask with an oesophageal vent. *Br J Anaesth* 2000; 84: 650–4.
  - 5 *Keller C, Brimacombe J*. Mucosal pressure and oropharyngeal leak pressure with the ProSeal versus laryngeal mask airway in anaesthetized paralysed patients. *Br J Anaesth* 2000; 85: 262–6.
  - 6 *Brimacombe J, Keller C, Fullekrug B, et al*. A multicenter study comparing the ProSeal and Classic laryngeal mask airway in anesthetized, nonparalyzed patients. *Anesthesiology* 2002; 96: 289–95.
  - 7 *Kihara S, Brimacombe J*. Sex-based ProSeal laryngeal mask airway size selection: a randomized crossover study of anesthetized, paralyzed male and female adult patients. *Anesth Analg* 2003; 97: 280–4.
  - 8 *Keller C, Brimacombe JR, Keller K, Morris R*. Comparison of four methods for assessing airway sealing pressure with the laryngeal mask airway in adult patients. *Br J Anaesth* 1999; 82: 286–7.
  - 9 *Brimacombe J, Berry A*. A proposed fiber-optic scoring system to standardize the assessment of laryngeal mask airway position. *Anesth Analg* 1993; 76: 457.
  - 10 *Ahmed MZ, Vohra A*. The reinforced laryngeal mask airway (RLMA) protects the airway in patients undergoing nasal surgery--an observational study of 200 patients. *Can J Anesth* 2002; 49: 863–6.
  - 11 *Cook TM, Nolan JP, Verghese C, et al*. Randomized crossover comparison of the proseal with the classic laryngeal mask airway in unparalysed anaesthetized patients. *Br J Anaesth* 2002; 88: 527–33.
  - 12 *Lu PP, Brimacombe J, Yang C, Shyr M*. ProSeal versus the Classic laryngeal mask airway for positive pressure ventilation during laparoscopic cholecystectomy. *Br J Anaesth* 2002; 88: 824–7.
  - 13 *Ahmed SM, Maroof M, Khan RM, Singhal V, Rizvi KA*. A comparison of the laryngeal mask airway and PA(Xpress) for short surgical procedures. *Anesthesia* 2003; 58: 42–4.
  - 14 *Evans NR, Gardner SV, James MF, et al*. The proseal laryngeal mask: results of a descriptive trial with experience of 300 cases. *Br J Anaesth* 2002; 88: 534–9.